Please enable JavaScript to continue using this application.

Compare $CUE vs $LYEL | Chartloom

Compare

$CUE vs $LYEL

Cue Biopharma Inc · Lyell Immunopharma Inc

CUE

Cue Biopharma Inc

LYEL

Lyell Immunopharma Inc

Compare $CUE vs $LYEL

Comparing Cue Biopharma Inc and Lyell Immunopharma Inc

CUECue Biopharma Inc

LYELLyell Immunopharma Inc

CUECue Biopharma Inc

Market cap

$112M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

354.4%

YTD performance

173.6%

52W performance

7.5%

FCF yield

-44.8%

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CUE

LYEL

Detailed metrics comparison

CUE

Cue Biopharma Inc

LYEL

Lyell Immunopharma Inc

Market Cap

CUE$112M

LYEL$203M

Enterprise Value

CUE$95M

LYEL$130M

Price

CUE$27.66

LYEL$8.71

P/E Ratio

CUEN/A

LYELN/A

P/S Ratio

CUE2.98x

LYEL7,526.09x

EV/Sales

CUE2.51x

LYEL4,822.94x

EV/EBITDA

CUE0.00x

LYEL0.00x

P/B Ratio

CUE80.41x

LYEL0.97x

P/FCF Ratio

CUEN/A

LYELN/A

EV/FCF

CUE-1.89x

LYEL-0.74x

PEG Ratio

CUEN/A

LYELN/A

Forward P/E (NTM)

CUEN/A

LYELN/A

Forward P/S (NTM)

CUEN/A

LYEL16,911.71x

Revenue (TTM)

CUE$38M

LYEL$27K

Revenue Growth (YoY)

CUE354.4%

LYEL-55.0%

Forward Rev Growth

CUE-38.2%

LYEL7184.7%

Gross Margin (TTM)

CUE0.0%

LYEL0.0%

Operating Margin (TTM)

CUE0.0%

LYEL0.0%

EBITDA Margin (TTM)

CUE-258.4%

LYEL-669059.3%

Net Margin (TTM)

CUE-435.8%

LYEL-920285.2%

FCF Margin (TTM)

CUE-133.2%

LYEL-648763.0%

Net Income (TTM)

CUE$-164M

LYEL$-248M

FCF (TTM)

CUE$-50M

LYEL$-175M

EPS (TTM)

CUE-$25.88

LYEL-$10.64

ROE (TTM)

CUE-103219.0%

LYEL-9162.0%

ROA (TTM)

CUE-48467.0%

LYEL-7050.0%

ROIC (TTM)

CUE-100612.0%

LYEL-9162.0%

Cash

CUE$17M

LYEL$73M

Debt

CUE$0

LYEL$0

Net Cash/Debt

CUE$17M

LYEL$73M

Current Ratio (TTM)

CUE1.25x

LYEL5.36x

Quick Ratio (TTM)

CUE1.16x

LYEL5.12x

Debt/Equity (TTM)

CUE0.00x

LYEL0.00x

Debt/Assets (TTM)

CUE0.0%

LYEL0.0%

Interest Coverage (TTM)

CUEN/A

LYELN/A

Net Debt/EBITDA (TTM)

CUE0.00x

LYEL0.00x

Beta

CUE2.84

LYEL-0.04

52W Performance

CUE7.5%

LYEL-52.3%

YTD Performance

CUE173.6%

LYEL-69.9%

% from 52W High

CUE-39.2%

LYEL-80.6%

% from 52W Low

CUE456.4%

LYEL6.1%

Asset Turnover (TTM)

CUE1.11x

LYEL0.00x

FCF Yield (TTM)

CUE-44.8%

LYEL-86.2%

Earnings Yield (TTM)

CUE-146.5%

LYEL-122.3%

Dividend Yield (TTM)

CUEN/A

LYELN/A

Rule of 40

CUE221.1

LYEL-648,818.0

EV/GP/RG

CUEN/A

LYELN/A

Ticker research

View CUE research View LYEL research

Metric	CUE Cue Biopharma Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$112M	$203M
Enterprise Value	$95M	$130M
Price	$27.66	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	2.98x	7,526.09x
EV/Sales	2.51x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	80.41x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.89x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	16,911.71x
Revenue & Growth
Revenue (TTM)	$38M	$27K
Revenue Growth (YoY)	354.4%	-55.0%
Forward Rev Growth	-38.2%	7184.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-258.4%	-669059.3%
Net Margin (TTM)	-435.8%	-920285.2%
FCF Margin (TTM)	-133.2%	-648763.0%
Net Income (TTM)	$-164M	$-248M
FCF (TTM)	$-50M	$-175M
EPS (TTM)	-$25.88	-$10.64
ROE (TTM)	-103219.0%	-9162.0%
ROA (TTM)	-48467.0%	-7050.0%
ROIC (TTM)	-100612.0%	-9162.0%
Financial Health
Cash	$17M	$73M
Debt	$0	$0
Net Cash/Debt	$17M	$73M
Current Ratio (TTM)	1.25x	5.36x
Quick Ratio (TTM)	1.16x	5.12x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.84	-0.04
52W Performance	7.5%	-52.3%
YTD Performance	173.6%	-69.9%
% from 52W High	-39.2%	-80.6%
% from 52W Low	456.4%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	1.11x	0.00x
FCF Yield (TTM)	-44.8%	-86.2%
Earnings Yield (TTM)	-146.5%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	221.1	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View CUE research	View LYEL research

Valuation

P/S Ratio

CUE

2.98x

LYEL

7,526.09x

EV/FCF

CUE

-1.89x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

CUE

354.4%

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

CUE

-38.2%

Profitability & performance

Gross Margin

CUE

0.0%

LYEL

0.0%

ROE

LYEL

-9162.0%

CUE

-103219.0%

FCF Yield %

CUE

-44.8%

LYEL

-86.2%

52-Week Performance

CUE

7.5%

LYEL

-52.3%

Detailed metrics comparison

CUE

Cue Biopharma Inc

LYEL

Lyell Immunopharma Inc

Market Cap

CUE$112M

LYEL$203M

Enterprise Value

CUE$95M

LYEL$130M

Price

CUE$27.66

LYEL$8.71

P/E Ratio

CUEN/A

LYELN/A

P/S Ratio

CUE2.98x

LYEL7,526.09x

EV/Sales

CUE2.51x

LYEL4,822.94x

EV/EBITDA

CUE0.00x

LYEL0.00x

P/B Ratio

CUE80.41x

LYEL0.97x

P/FCF Ratio

CUEN/A

LYELN/A

EV/FCF

CUE-1.89x

LYEL-0.74x

PEG Ratio

CUEN/A

LYELN/A

Forward P/E (NTM)

CUEN/A

LYELN/A

Forward P/S (NTM)

CUEN/A

LYEL16,911.71x

Revenue (TTM)

CUE$38M

LYEL$27K

Revenue Growth (YoY)

CUE354.4%

LYEL-55.0%

Forward Rev Growth

CUE-38.2%

LYEL7184.7%

Gross Margin (TTM)

CUE0.0%

LYEL0.0%

Operating Margin (TTM)

CUE0.0%

LYEL0.0%

EBITDA Margin (TTM)

CUE-258.4%

LYEL-669059.3%

Net Margin (TTM)

CUE-435.8%

LYEL-920285.2%

FCF Margin (TTM)

CUE-133.2%

LYEL-648763.0%

Net Income (TTM)

CUE$-164M

LYEL$-248M

FCF (TTM)

CUE$-50M

LYEL$-175M

EPS (TTM)

CUE-$25.88

LYEL-$10.64

ROE (TTM)

CUE-103219.0%

LYEL-9162.0%

ROA (TTM)

CUE-48467.0%

LYEL-7050.0%

ROIC (TTM)

CUE-100612.0%

LYEL-9162.0%

Cash

CUE$17M

LYEL$73M

Debt

CUE$0

LYEL$0

Net Cash/Debt

CUE$17M

LYEL$73M

Current Ratio (TTM)

CUE1.25x

LYEL5.36x

Quick Ratio (TTM)

CUE1.16x

LYEL5.12x

Debt/Equity (TTM)

CUE0.00x

LYEL0.00x

Debt/Assets (TTM)

CUE0.0%

LYEL0.0%

Interest Coverage (TTM)

CUEN/A

LYELN/A

Net Debt/EBITDA (TTM)

CUE0.00x

LYEL0.00x

Beta

CUE2.84

LYEL-0.04

52W Performance

CUE7.5%

LYEL-52.3%

YTD Performance

CUE173.6%

LYEL-69.9%

% from 52W High

CUE-39.2%

LYEL-80.6%

% from 52W Low

CUE456.4%

LYEL6.1%

Asset Turnover (TTM)

CUE1.11x

LYEL0.00x

FCF Yield (TTM)

CUE-44.8%

LYEL-86.2%

Earnings Yield (TTM)

CUE-146.5%

LYEL-122.3%

Dividend Yield (TTM)

CUEN/A

LYELN/A

Rule of 40

CUE221.1

LYEL-648,818.0

EV/GP/RG

CUEN/A

LYELN/A

Ticker research

View CUE research View LYEL research

Metric	CUE Cue Biopharma Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$112M	$203M
Enterprise Value	$95M	$130M
Price	$27.66	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	2.98x	7,526.09x
EV/Sales	2.51x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	80.41x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.89x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	16,911.71x
Revenue & Growth
Revenue (TTM)	$38M	$27K
Revenue Growth (YoY)	354.4%	-55.0%
Forward Rev Growth	-38.2%	7184.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-258.4%	-669059.3%
Net Margin (TTM)	-435.8%	-920285.2%
FCF Margin (TTM)	-133.2%	-648763.0%
Net Income (TTM)	$-164M	$-248M
FCF (TTM)	$-50M	$-175M
EPS (TTM)	-$25.88	-$10.64
ROE (TTM)	-103219.0%	-9162.0%
ROA (TTM)	-48467.0%	-7050.0%
ROIC (TTM)	-100612.0%	-9162.0%
Financial Health
Cash	$17M	$73M
Debt	$0	$0
Net Cash/Debt	$17M	$73M
Current Ratio (TTM)	1.25x	5.36x
Quick Ratio (TTM)	1.16x	5.12x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.84	-0.04
52W Performance	7.5%	-52.3%
YTD Performance	173.6%	-69.9%
% from 52W High	-39.2%	-80.6%
% from 52W Low	456.4%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	1.11x	0.00x
FCF Yield (TTM)	-44.8%	-86.2%
Earnings Yield (TTM)	-146.5%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	221.1	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View CUE research	View LYEL research